A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease

Trial Profile

A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 May 2017

At a glance

  • Drugs QBECO (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Qu Biologics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2017 According to a Qu Biologics media release, data from this trial will be presented at Digestive Disease Week (DDW).
    • 19 Apr 2017 Results published in a Qu Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top